Key Highlights
- Starling Oncology, Inc. shares are up approximately 33% in pre-market trading.
- Q2 revenue reached $161.3 million, up 34.6% year-over-year, beating estimates.
- Gross profit rose 55%, the net loss narrowed, and adjusted EBITDA turned positive.
- The company raised full-year 2026 revenue guidance to $650 million to $670 million.
Starling Oncology, Inc. (NASDAQ: STLN), formerly The Oncology Institute and recently rebranded with a new ticker, saw shares rise approximately 33% in pre-market trading on August 7, 2026, after the value-based community oncology provider reported Q2 results with revenue of $161.3 million, up 34.6% year-over-year, beating estimates.
What Happened
Gross profit rose 55%, the net loss narrowed, and adjusted EBITDA turned positive, marking a notable inflection in the company's profitability trajectory alongside the strong revenue growth.
The company also signed new delegated contracts outside Florida and raised full-year 2026 revenue guidance to $650 million to $670 million, indicating the growth seen this quarter is expected to continue expanding geographically.
Management highlighted progress on a new provider portal and exclusivity agreements, additional operational developments supporting the company's broader value-based care platform.
Value-based oncology care models depend heavily on scaling delegated risk contracts across new geographies, making the expansion outside Florida a particularly meaningful signal of the company's ability to replicate its care model beyond its original core market.
Market Reaction
The revenue beat, improved profitability trajectory, and higher outlook drove the pre-market move, with the swing to positive adjusted EBITDA likely serving as a particularly meaningful signal for a company that has faced questions about its path to sustained profitability.
The new delegated contracts outside Florida suggest the company's value-based care model is gaining traction beyond its historical core market, a geographic expansion signal that appears to have reinforced investor confidence in the raised full-year guidance.
Recently rebranded companies often face additional scrutiny from investors seeking confirmation that the name change reflects genuine strategic repositioning rather than a purely cosmetic update, making this quarter's operational proof points especially relevant to the market's reaction.
Outlook
Continued expansion of delegated contracts outside Florida, progress on the new provider portal, and sustained positive adjusted EBITDA are likely to remain the key factors shaping sentiment toward Starling Oncology's stock as it works toward its raised full-year 2026 revenue guidance of $650 million to $670 million.
As a recently rebranded company, continued consistency in financial performance under the new Starling Oncology identity is likely to be an important factor in building longer-term investor confidence beyond this single quarter's results.






Please wait processing your request...